Viking Therapeutics heats up competition in obesity with impressive Phase 2 data
Arctic Aurora portfolio company Viking Therapeutics opened nearly 100% up on positive weight loss data from a Phase 2 study
Obesity is one of the largest societal and healthcare burdens globally. It is estimated to affect more than 650 million people, who are at a higher risk of developing more than 200 health complications including diabetes, cardiovascular problems, and fatty liver disease. In the recent years, multiple drugs have been developed to address this global challenge.
Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company Viking Therapeutics is a strong contender in the obesity space. Today, they announced competitive Phase 2 results of their drug candidate, VK2735. Obese patients in the trial achieved a placebo-adjusted weight loss of up to 13.1% after just 13 weeks. Importantly, weight loss did not plateau at 13 weeks and the treatment was effective in most patients with 88% of them achieving a ≥10% weight loss at the end of the trial. The side effects of the drug were comparable to other similar treatments.
VK2735 is a dual activator of the glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Effect on these receptors is associated with reduced body weight and appetite, and higher sensitivity to insulin. Among the drugs that are already approved, semaglutide (brand name Ozempic/Wegovy, marketed by Novo Nordisk) acts on GLP-1 while tirzepatide (Mounjaro/Zepbound by Eli Lilly) is a dual activator of the GLP-1/GIP receptors similarly to VK2735. According to consensus, the size of the obesity market will reach USD 100-150 billion and the peak sales of semaglutide and tirzepatide are expected to be USD 40 billion and USD 45 billion, respectively.
Latest news
Arctic Asset Management - Arctic Midt i Måneden - Hvordan bruker proffene informasjonsflyten i rapporteringssesongen
I denne episoden av Arctic Midt i Måneden er aksjeforvalter Ole Dahl og analytiker Arild Huitfeldt på besøk i studio hos Albert Collett, der de gir innblikk i hvordan de jobber for å oppnå best mulig avkastning for investorene.
Arctic Asset Management - Biopharma is finally improving depression treatment outcomes and providing more options to patients
On Tuesday April 16, psychiatry specialists, and Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding, Intra-Cellular Therapies rallied nearly 25% on positive Phase 3 clinical trial depression results. The news adds to the list of good news in the treatment landscape for Major Depressive Disorder or MDD, colloquially known as depression.
Arctic Asset Management - Markedskommentar Mars 2024
Mars ble en bra børsmåned internasjonalt, og det var bredde i oppgangen med alle sektorer i S&P500 og nær alle sektorer på Oslo Børs og i Norden opp. En god måned også for kreditt, med stigning i DNBs Nordiske High Yield indeks og fall i kredittpåslagene både i USA og Europa. Sentralbankene signaliserte reduserte forventninger til fremtidige rentekutt, og ble mer tydelige på når første rentekutt kommer. Markedet priset som følge inn færre rentekutt enn tidligere.
Arctic Asset Management - Emerging gene therapies provide new option to children wilth Duchenne Muscular Dystrophy
Multiple companies develop gene therapies to improve the state of children suffering from Duchenne Muscular Dystrophy, a rare and debilitating genetic disease that leads to muscle degeneration and substantially reduced life expectancy.
Arctic Asset Management - Arctic Midt i Måneden - Det er på tide å kalle på spesialistene
Ulrica Slåne Bjerke, forvalter for Arctic Aurora LifeScience, er i studio for å fortelle hvordan de skaper avkastning for helsefondet som har levert 160% siden oppstart i 2016.
Arctic Asset Management - Markedskommentar Februar 2024
Bedring i makroøkonomiske nøkkeltall ga oppgang for både statsrenter og aksjemarked i februar. Den nordiske Vinx-indeksen, amerikanske S&P 500 og verdensindeksen viste god månedsavkastning, mens det norske aksjemarkedet (OSEFX i NOK) berget seg på riktig side av streken i februar. Som i 2023, var det spredning i feltet der noen få, store aksjer sto for mye av avkastningen.